ANTICOAGULANT TREATMENT IN PATIENTS WITH RENAL INSUFFICIENCY
Abstract
BACKGROUND In the recent years, the number of patients treated with anticoagulant therapy isincreasing. Among them, there is also an increased number of patients with renal insufficiency.Due to changes in coagulation and fibrinolityc system activity these patients are atincreased risk of bleeding and thrombotic complications when treated with anticoagulants.Unfractionated heparin, low-molecular-weight-heparins and vitamin K antagonistare used for anticoagulant therapy in patients with renal insufficiency. Dosing of unfractionatedheparin and vitamin K antagonists in these patients does not differ fromdosing in patients without renal disease. However, special caution should be taken whenusing low molecular weight heparins for therapy or prophylaxis in patients with renalinsufficiency. Low-molecular-weight-heparins are cleared principally by renal route andtheir biological half-life is prolonged in patients with renal insufficiency. If low-molecularweight-heparin is chosen for anticoagulant therapy, monitoring should be performed withanti-factor Xa activity measurements.Clinicians are often required to decide on how to manage patients receiving long-termanticoagulant therapy during and after invasive nephrological procedures. CONCLUSIONS This article summarizes recommendations on use of anticoagulant drugs in patientswith renal insufficiency. It also suggests management of these patients before and afterinvasive nephrological procedures including renal transplantationDownloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
